Trxade Group (MEDS)
(Delayed Data from NSDQ)
$7.90 USD
+0.21 (2.73%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $7.94 +0.04 (0.51%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
MEDS 7.90 +0.21(2.73%)
Will MEDS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for MEDS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MEDS
Eton Pharmaceuticals, Inc. (ETON) Tops Q2 Earnings and Revenue Estimates
Charles River Laboratories (CRL) Beats Q2 Earnings and Revenue Estimates
MEDS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biodesix, Inc. (BDSX) Reports Q2 Loss, Tops Revenue Estimates
DermTech, Inc. (DMTK) Reports Q2 Loss, Tops Revenue Estimates
TRxADE (MEDS) Reports Q1 Loss, Lags Revenue Estimates
Other News for MEDS
TRxADE Health, Inc. Announces New Addition and Changes to Scienture, LLC?s Executive Leadership Team
Trxade Health appoints Mani as President, Hariharan as CEO of Scienture
Trxade Group’s Strategic Merger and Rebranding as Scienture Holdings
Trxade Health acquires Scienture in all-stock transaction valued at $103M
TRxADE Health, Inc. Announces Business Combination with Scienture, Inc., in a Transaction Valued at $103 Million